Hair Transplants: When They Actually Make Sense

By Dr. Susan Lin, MD | MD HAIR | La Cañada Ventures, Inc.
Published on mdhair.com — Drug-Free Hair Regrowth Series

You have reached the point where you are looking at flights. The consultation was free, the quote came back at a number you could just about manage, and the clinic's Instagram is wall-to-wall with hairlines that look like they were drawn by someone with taste. Somebody in the comments says it changed their life. You believe them.

And underneath all of that is a quieter feeling you have not said out loud: that this is the permanent one. The end of the ritual. No more bottles, no more waiting for the six-month photograph, no more checking the drain. One procedure, and then you are done thinking about it.

I want to be useful to you here, so let me start with the sentence that transplant marketing is structurally incapable of leading with, and that almost every honest surgeon will say to your face in the consultation room:

A hair transplant moves hair you already have from one part of your head to another. It does not stop the process that is thinning the rest.

That is not a criticism of the procedure. Transplantation is real surgery with a real, durable, mechanistically well-understood result, and for the right patient it is the most visually transformative intervention in this entire field — far beyond anything I make. MD HAIR does not perform transplants, does not refer for them, and has no financial relationship with any surgeon or clinic. I am not competing with your surgeon. I am trying to make sure you understand what you are buying, because the failure mode of a transplant is not usually a bad graft. It is a good graft placed in front of an unaddressed condition.

The Mechanism: Donor Dominance

The reason a transplant works at all is a single biological observation, made in the 1950s and reconfirmed continuously since.

Follicles at the back and sides of the scalp — the occipital and lateral bands — are intrinsically less sensitive to androgens than those at the frontal hairline and vertex. Identical circulating DHT reaches all of them, but they do not miniaturise in response. That is why the classic pattern is a horseshoe: the hair that survives is not hair that was protected, it is hair that was never susceptible.

The critical finding is that this resistance is a property of the follicle itself, not of the skin it sits in. Orentreich named this donor dominance: transplanted follicles retain the characteristics of the region they came from, not of the region they were moved to (Orentreich, 1959). Move an androgen-resistant occipital follicle to the frontal scalp and it grows there, largely indifferent to the DHT environment that destroyed its neighbours.

That is the whole trick. It is elegant, it is real, and it explains both what a transplant can promise and what it structurally cannot.

It can promise: hair in a place where you currently have none, growing from follicles that are unlikely to miniaturise.

It cannot promise: anything at all about the native, susceptible hair still sitting around and behind the transplanted grafts.

FUE and FUT, Briefly

Two harvesting methods dominate. Both move follicular units — the natural clusters of one to four hairs in which scalp hair actually grows (Bernstein & Rassman, 1997).

FUT (follicular unit transplantation), also called strip harvesting. A strip of scalp is excised from the donor area, the wound is closed, and the strip is dissected under magnification into individual follicular units. It leaves a linear scar across the back of the head, hidden by hair of adequate length. Its advantages are efficiency of graft yield from a given area of donor scalp and, in many surgeons' hands, high transection quality.

FUE (follicular unit excision/extraction). Individual follicular units are removed directly from the donor area with a small punch, typically under a millimetre (Rassman et al., 2002). There is no linear scar; instead there are many tiny circular scars, which are far less conspicuous and permit shorter haircuts. FUE requires the donor area to be shaved (in most protocols), takes longer, and can, if performed too aggressively over a broad area, produce visible donor thinning.

How to think about the choice. This is genuinely a surgeon's judgement, made on your donor density, your scalp laxity, the number of grafts required and how short you intend to wear your hair. Do not let a clinic sell you a method as a brand. The method matters far less than the operator — and I will come back to that.

Both are performed under local anaesthetic, both take most of a day for a large session, and in both the transplanted hairs shed within the first few weeks before regrowing. That shed is expected and is not graft failure. Meaningful cosmetic assessment is at nine to twelve months.

Donor Supply Is the Real Constraint

Here is the arithmetic that governs everything, and that clinics quoting per-graft prices have every incentive to leave implicit.

You have a finite number of androgen-resistant follicles, and no procedure creates more of them. Transplantation is redistribution from a fixed account. Every graft moved forward is a graft permanently withdrawn from the donor area.

Three consequences follow, and they are the three things I would want you to hold in your head during a consultation:

1. The donor area has a floor. Harvest too much and the donor region itself becomes visibly thin — a see-through back of the head, which is both conspicuous and irreversible. A responsible surgeon plans a lifetime harvest budget, not a single session's maximum.

2. Coverage is a trade, not an addition. A transplant does not increase your total hair. It relocates density from a place where you have a surplus to a place where you have none. Full, youthful frontal density often requires more grafts than your donor area can safely spare — which is why experienced surgeons will sometimes offer you a conservative hairline and a modest density rather than the photograph you brought in.

3. Loss keeps moving, so today's plan must survive tomorrow's pattern. This is the one that produces the disasters.

Why Your Native Hair Keeps Receding Around the Grafts

Picture the mechanism honestly. A surgeon places 2,000 androgen-resistant grafts along a new frontal hairline. Immediately behind them sits your native, androgen-susceptible hair, still carrying the same receptor biology it had the day before surgery, still exposed to the same DHT.

Nothing about the operation changed that. So over the following years, the native hair behind the graft line continues to miniaturise on its own schedule.

The result is one of the recognisable failure patterns in this field: a dense, permanent transplanted hairline with a widening zone of thinning behind it. In the worst cases it produces an isolated island of hair sitting in front of bare scalp — a result that is not merely disappointing but conspicuous, because it does not correspond to any pattern that occurs in nature.

There is a second version of the same problem. A patient with early loss gets a low, straight, aggressive hairline at twenty-four. At thirty-eight, the pattern has advanced to a stage that would naturally have placed the hairline several centimetres higher. Now the transplanted line is not a restoration; it is a stripe. And because donor supply was spent creating it, the grafts needed to blend it into the new reality may no longer exist.

This is the mechanism behind the single most important sentence in transplant medicine, and it is worth stating without decoration: a transplant is a redistribution procedure layered on top of an ongoing, progressive condition, and the ongoing condition has to be managed separately or the redistribution ages badly.

Why Good Surgeons Decline Young Patients

If a surgeon tells a twenty-three-year-old to come back in a few years, that surgeon is doing their job. Here is why.

The pattern is not finished. Androgenetic alopecia is progressive, and its eventual extent is not knowable early. Operating in year two of a process that will run for thirty years means designing around a map you cannot yet read. Surgeons plan against the pattern they must assume the patient will reach, not the one in front of them.

Diffuse early loss is a trap. Young patients often present with generalised thinning rather than a defined recession. A diffusely thinning scalp can also be diffusely thinning at the back — meaning the donor area is itself affected, a situation sometimes described as diffuse unpatterned alopecia. Grafts taken from a donor zone that is quietly miniaturising will thin later in their new location, because donor dominance carries the donor's fate with it. If the donor is not stable, the whole premise of the operation fails.

Donor supply spent early is spent forever. The younger the patient, the more future demand there will be on a fixed account.

And the diagnosis itself deserves scrutiny at that age. Early, rapid or unusual loss warrants a proper workup rather than a scalpel.

A clinic that will operate on any patient who can pay is not exercising surgical judgement. It is processing orders. The willingness to say no is one of the strongest quality signals available to you.

What a Transplant Cannot Fix

Be clear-eyed about the exclusions. A transplant is the wrong tool if:

  • You have diffuse thinning without a stable donor area. No donor, no operation. This is the most common honest decline.
  • You have active scarring (cicatricial) alopecia — lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia, folliculitis decalvans. In these conditions the follicle is destroyed and replaced with fibrous tissue by an active inflammatory process (Harries et al., 2008). Grafts placed into actively inflamed scalp can be lost to the same process. Surgery in scarring alopecia is only considered after the disease has been quiescent for a sustained period, under dermatological supervision, and often with a test session first.
  • You have active alopecia areata, an autoimmune condition that is not a redistribution problem at all.
  • Your hair loss has an undiagnosed medical cause. Thyroid disease, iron deficiency (Trost et al., 2006), an acute telogen effluvium after illness or surgery, rapid weight loss, a new medication, or an endocrine disorder. Every one of these can produce visible thinning, and none of them is improved by moving follicles around. Operating on an unworked-up patient means potentially performing surgery for a condition that would have resolved or that will keep progressing regardless.
  • Your expectation is the density you had at nineteen. Transplantation creates the appearance of coverage using a fraction of the original follicle count, by exploiting spacing, angle and the way light behaves on a scalp. It is very good at this. It is not a restoration of original density, and a surgeon who promises one is not being straight with you.

Cost, and What Is Really Being Priced

Pricing is usually quoted per graft, commonly in the region of $2 to $10 per graft in the United States depending on method and market, with sessions of 1,500 to 3,000+ grafts — so a single procedure frequently lands between roughly $5,000 and $20,000, with extensive cases higher, and clinics abroad advertise substantially lower package prices.

Two things about that number.

First, per-graft pricing invites the wrong comparison. A cheaper graft is not a better deal if it is transected during harvest, planted at the wrong angle, or taken from a donor zone that should not have been touched. You are not buying grafts; you are buying judgement, technique and follow-up.

Second, the quoted number is rarely the total. Budget for consultation, medications, time away from work, travel where relevant, and the real possibility of a second session — either to add density or to address progression. Many patients have more than one procedure over a lifetime.

How to Choose a Surgeon

The evidence base here is unusual: outcomes in transplantation are less about technology and more about operator skill and case selection than almost anywhere else in cosmetic medicine (Kerure & Patwardhan, 2018). Choose accordingly.

  • Confirm the surgeon's actual credentials and licensure, in the jurisdiction where the operation will happen. Verify it independently; do not accept a website badge.
  • Establish who does what. In many clinics, technicians perform substantial parts of the procedure. That is not inherently wrong — experienced teams are a genuine asset — but you are entitled to know exactly which steps the surgeon personally performs, and how many cases they run per day. A surgeon running several simultaneous cases is dividing something you are paying for.
  • Ask to see unretouched results in patients with your hair type, colour, texture and loss pattern, photographed under a consistent standard, at twelve months. Ask specifically for a result they consider a poor one and what they learned from it. The answer to that question is worth more than the portfolio.
  • Ask about their revision policy and what happens if graft survival is poor.
  • Ask what they would decline. A surgeon with no exclusion criteria has no standards.
  • Watch how they handle your hairline design. A conservative, appropriately mature hairline with rounded temporal recession, single-hair grafts at the leading edge and irregular spacing is the mark of someone designing for your forties. A low, straight, dense line is the mark of someone designing for your Instagram post next month.
  • Be careful with international package deals. They can be excellent value and some overseas clinics are outstanding. But price-led medical tourism concentrates exactly the incentives described above — high volume, technician-led work, aggressive graft counts, and no realistic access to follow-up if something goes wrong. If you go, apply the same questions, harder.

The One Question Most Patients Forget

If you take a single practical instruction from this article, take this one.

Ask your surgeon: What do you recommend for the hair I am not transplanting?

Because that is the hair that determines whether your result still looks right in a decade. The grafts are the part the surgery handles. The native, susceptible hair behind and around them is the part it does not — and it is where the long-term outcome is actually decided.

That conversation belongs to your surgeon and your own physician, with your full history in front of them. It is a medical decision about an ongoing condition, made by the people responsible for your care. I am deliberately not going to tell you what that plan should be, and you should be suspicious of any product website that does. Ask them, write down the answer, and hold them to it at your follow-ups.

The Bottom Line

Hair transplantation rests on a genuine and well-established biological fact — donor dominance — and for a well-selected patient it produces the most visually dramatic result available in this field. It is real surgery, and it is not a scam.

It is also a redistribution of a finite resource, performed on top of a condition that keeps progressing underneath it. That single fact generates every one of its limits: the fixed donor budget, the conservative hairline, the surgeon's reluctance to operate on the young, the requirement for a stable donor area, and the necessity of a separate plan for the hair that was never moved.

The candidates who do well are the ones with stable, defined, patterned loss, adequate donor supply, a correctly worked-up medical picture, realistic expectations, and a surgeon willing to tell them no. The ones who do badly are usually people who were operated on too early, too aggressively, or for the wrong diagnosis.

Get the medical workup first. Ask the kinds of question above. And ask about the hair you are not transplanting.

Dr. Susan Lin's Clinical Perspective

"There is no drug-free formulation on earth, mine included, that produces what a well-executed transplant produces on a bald frontal scalp. I say that plainly because a brand that pretends otherwise has forfeited the right to be believed about anything else. What I ask patients to notice is the shape of the operation: it relocates androgen-resistant follicles into a field of androgen-susceptible ones, and it leaves the susceptible ones exactly as it found them. The commonest bad outcome I encounter is not a technical failure — it is a beautiful hairline with a widening desert behind it, in a patient nobody worked up and nobody counselled about progression. Get the diagnosis first, choose the surgeon who is willing to decline you, and ask what happens to the hair that stays where it is."

— Dr. Susan F. Lin, M.D., Physician Formulator, MD HAIR

Mechanism Spotlight: Why Occipital Follicles Survive — and What That Means for the Donor Budget

The horseshoe is not luck. Frontal and vertex follicles carry higher androgen receptor density and greater local 5-alpha-reductase activity than occipital follicles, so identical circulating DHT produces very different receptor signalling depending on where a follicle sits. Genetic work has established variation at the androgen receptor locus as a major determinant of this susceptibility (Ellis et al., 2001; Hillmer et al., 2005). Regional programming, not regional exposure, is what decides which follicles miniaturise.

Orentreich's contribution was to show that the programming travels with the follicle. Grafts transplanted from resistant donor scalp into susceptible recipient scalp keep behaving like donor tissue — donor dominance (Orentreich, 1959).

The clinical arithmetic follows directly, and it is worth making concrete. The safe donor zone is a defined band; only a proportion of its follicular units can be harvested before visible donor thinning appears. That yields a lifetime graft budget which is fixed at birth by your own follicle count and cannot be increased by any technique. Every session spends from it permanently.

So the surgeon's real skill is not extraction speed. It is allocation: deciding how much of a non-renewable account to spend now, against a pattern of loss that has not finished expressing itself, in a patient who may need coverage in a different place twenty years from now.

Recommended Reading

Pillar pages on mdhair.com:

Related articles in this series:

Our sister site md-factor.com carries the wider MD® science library under the same evidence standard applied here.

MD HAIR Product Recommendation

None. This article is about someone else's operating theatre, and a product placement here would be exactly the kind of thing that should make you distrust a brand. If a transplant is right for you, have the transplant.

One link instead:

The MD HAIR Quiz — a structured way to think through what is actually driving your hair change before you book a surgical consultation. It is a starting point for reasoning, not a diagnosis, and several of its outcomes point to a physician and a lab panel rather than to any product or procedure.

And to repeat the instruction that matters most: ask your surgeon what they recommend for the hair you did not transplant. That plan is theirs to make with you, not mine.

A note on authenticity: genuine MD HAIR™ and MD Nutri Hair™ products are sold only through mdhair.com, md-factor.com, and the official La Cañada Ventures, Inc. stores on Amazon and Walmart. We cannot verify the storage, handling or lot integrity of units bought anywhere else.

References

  1. Orentreich N. (1959). Autografts in alopecias and other selected dermatological conditions. Annals of the New York Academy of Sciences, 83, 463–479. PMID 14429008
  2. Rassman WR, Bernstein RM, McClellan R, Jones R, Worton E, Uyttendaele H. (2002). Follicular unit extraction: minimally invasive surgery for hair transplantation. Dermatologic Surgery, 28(8), 720–728. PMID 12174065
  3. Bernstein RM, Rassman WR. (1997). Follicular transplantation: patient evaluation and surgical planning. Dermatologic Surgery, 23(9), 771–784. PMID 9311372
  4. Kerure AS, Patwardhan N. (2018). Complications in hair transplantation. Journal of Cutaneous and Aesthetic Surgery, 11(4), 182–189. PMID 30886471
  5. Ellis JA, Stebbing M, Harrap SB. (2001). Polymorphism of the androgen receptor gene is associated with male pattern baldness. Journal of Investigative Dermatology, 116(3), 452–455. PMID 11231320
  6. Hillmer AM, Hanneken S, Ritzmann S, et al. (2005). Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. American Journal of Human Genetics, 77(1), 140–148. PMID 15902657
  7. Harries MJ, Sinclair RD, Macdonald-Hull S, Whiting DA, Griffiths CEM, Paus R. (2008). Management of primary cicatricial alopecias: options for treatment. British Journal of Dermatology, 159(1), 1–22. PMID 18489608
  8. Trost LB, Bergfeld WF, Calogeras E. (2006). The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. Journal of the American Academy of Dermatology, 54(5), 824–844. PMID 16635664
  9. International Society of Hair Restoration Surgery — patient guidance materials. ishrs.org/patients

Dr. Susan F. Lin, M.D. is the physician formulator behind MD HAIR and MD Nutri Hair™, product lines of La Cañada Ventures, Inc. — physician-formulated since 2008 under the MD® mark (U.S. Reg. No. 4,471,494). She trained at Boston University School of Medicine and is board-certified in Obstetrics & Gynecology and in Anti-Aging Medicine (A4M).

MD HAIR does not perform hair restoration surgery, does not refer patients to surgeons or clinics, and receives no compensation of any kind in connection with hair transplantation. Statements about surgical techniques and outcomes reflect the published literature and are not endorsements of any surgeon, clinic or method. Nothing here is pre- or post-operative advice; all surgical care, including anything applied to or taken for a transplanted scalp, is directed by your operating surgeon. Pricing figures are general market observations at the time of writing and vary by region and provider.

MD® products are cosmetics and dietary supplements manufactured in FDA-registered, GMP-compliant facilities. Facility registration is not product approval: MD® products are not FDA approved, and no cosmetic or dietary supplement is. Individual results vary. MD Nutri Hair™ is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Because there are no clinical data in pregnant or breastfeeding women, we do not advocate using MD HAIR products during pregnancy or lactation.

This article is for educational purposes and does not constitute medical or surgical advice. Do not start, stop, or change any medication or treatment plan without consulting your own physician.

Explore more in our Drug-Free Hair Regrowth series at mdhair.com/pages/drug-free-hair-loss-treatment